08:55 AM EDT, 07/25/2024 (MT Newswires) -- FAX Capital overnight Wednesday filed an early warning report regarding disposition of common shares in BioSyent ( BIOYF ) through the facilities of the TSX Venture Exchange.

FAX announced on July 23 that it disposed of 500,000 shares of BioSyent ( BIOYF ) at an average price of $10.05 per Share and received aggregate consideration of $5 million. Immediately prior to the disposition, FAX owned and controlled 2 million shares, representing 18% of the outstanding shares of BioSyent ( BIOYF ). FAX now owns and controls 1.5 million shares, equal to 13.7%.

In the future, FAX may acquire additional BioSyeny shares or dispose of its holdings, the company said.

BioSyent ( BIOYF ) is a publicly traded specialty pharmaceutical company which, through its wholly owned subsidiaries, BioSyent Pharma Inc. and BioSyent Pharma International Inc., sources, acquires or in-licences and further develops pharmaceutical and other healthcare products for sale in Canada and certain international markets.